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A B S T R A C TBackground: Patient-reported outcome (PRO) instruments for chil-
dren and adolescents are often included in clinical trials with the
intention of collecting data to support claims in a medical
product label. Objective: The purpose of the current task force report
is to recommend good practices for pediatric PRO research that is
conducted to inform regulatory decision making and support claims
made in medical product labeling. The recommendations are based
on the consensus of an interdisciplinary group of researchers who
were assembled for a task force associated with the International
Society for Pharmacoeconomics and Outcomes Research (ISPOR). In
those areas in which supporting evidence is limited or in which
general principles may not apply to every situation, this task force
report identiﬁes factors to consider when making decisions about the
design and use of pediatric PRO instruments, while highlighting
issues that require further research. Good Research Practices: Five
good research practices are discussed: 1) Consider developmental
differences and determine age-based criteria for PRO administration:
Four age groups are discussed on the basis of previous research (o5
years old, 5–7 years, 8–11 years, and 12–18 years). These age groups
are recommended as a starting point when making decisions, but
they will not ﬁt all PRO instruments or the developmental stage of
every child. Speciﬁc age ranges should be determined individually for
each population and PRO instrument. 2) Establish content validity of
pediatric PRO instruments: This section discusses the advantages ofsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.04.004
tza@unitedbiosource.com.
ondence to: Louis S. Matza, United BioSource Corpusing children as content experts, as well as strategies for concept
elicitation and cognitive interviews with children. 3) Determine
whether an informant-reported outcome instrument is necessary:
The distinction between two types of informant-reported measures
(proxy vs. observational) is discussed, and recommendations are
provided. 4) Ensure that the instrument is designed and formatted
appropriately for the target age group. Factors to consider include
health-related vocabulary, reading level, response scales, recall
period, length of instrument, pictorial representations, formatting
details, administration approaches, and electronic data collection
(ePRO). 5) Consider cross-cultural issues. Conclusions: Additional
research is needed to provide methodological guidance for future
studies, especially for studies involving young children and parents’
observational reports. As PRO data are increasingly used to support
pediatric labeling claims, there will be more information regarding
the standards by which these instruments will be judged. The use of
PRO instruments in clinical trials and regulatory submissions will
help ensure that children’s experience of disease and treatment are
accurately represented and considered in regulatory decisions.
Keywords: adolescents, children, ISPOR, medical product labeling,
patient-reported outcomes, pediatrics, PRO, task force.
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Background to the Task Force
In March 2009, the ISPOR Health Science Policy Council recom-
mended to the ISPOR Board of Directors that an ISPOR Good
Research Practices Patient-Reported Outcomes (PRO) Task Force
should be established to focus on the Assessment of Patient-
Reported Outcomes in Children and Adolescents. The Board of
Directors approved this PROTask Force inMarch 2009. The Pediatric
PRO Task Force chair (Dr. Matza) and co-chair (Dr. Patrick) chose
task force members based on their experience in PRO assessment
and research focusing specifically on children and adolescents.
Memberswere selected to represent a diverse range of perspectives,
including government (United States Food and Drug Administra-
tion), academia, research organizations, and the pharmaceutical
industry. In addition, the task force had international representa-
tion with members from Germany, Spain, and the United States.
The Task Force initially met approximately every 2 months by
teleconference to develop an outline and discuss issues to be
included in the report. Face-to-face meetings were held in New
Orleans in October 2009 and Atlanta in May 2010 to discuss these
issues further and come to consensus on recommendations. In
addition, the task force chair had a series of one-on-one
teleconferenceswithmembers involved in drafting themanuscript.
All task force members reviewed many drafts of the report and
provided frequent feedback in both oral and written comments.
Preliminary findings and recommendations were presented
in a forum at the ISPOR 15th Annual International Meeting in
May 2010. Updated findings and recommendations were pre-
sented in a forum at the ISPOR 17th Annual International
Meeting in June 2012. Comments received during these two
forums were addressed in subsequent drafts of the report.
A draft of this report was distributed to the ISPOR PRO Review
Group (which includes over 400 members) in March 2012. A
revised draft was distributed to the entire ISPOR membership in
January 2013. During these two rounds of review, over 250 written
comments were received from 40 ISPOR members. Written
comments were also provided by members of several regulatory
and reimbursement agencies including three reviewers from the
US Food and Drug Administration, one reviewer from Germany’s
Institute for Quality and Efficiency in Health Care (IQWiG), and
one reviewer representing both the French National Authority for
Health (Haute Autorite´ de Sante´ [HAS]) and the European Network
for Health Technology Assessment (EUnetHTA).
All comments were considered, and most were substantive
and constructive. The comments were discussed by the task
force in a series of teleconferences and addressed as appro-
priate in revised drafts of the report. Once consensus was
reached by all task force members, the final report was
submitted to Value in Health in April 2013.
All written comments are published at the ISPOR Web site on
the task force’s Web page: http://www.ispor.org/TaskForces/PRO
ChildrenAdolescents.asp. The task force report and Web page may
also be accessed from the ISPOR homepage (www.ispor.org) via the
purple Research Tools menu, Good Practices for Outcomes
Research, heading: Patient Centered & Clinician Reported Out-
comes Methods, and link: Assessment of PRO in Children and
Adolescents. A list of reviewers is also available via the task force’s
Web page.
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A patient-reported outcome (PRO) instrument involves the report of
health status coming directly from the patient without interpreta-
tion of the patient’s response by a clinician, investigator, or anyone
else [1,2]. Many aspects of medical conditions are known only by
the patients themselves, and direct assessment of the patient
perspective is necessary to thoroughly understand patients’ expe-
riences of disease and treatment. In recent years, there has been an
increased emphasis on systematic development and validation of
PRO instruments for use in clinical trials evaluating medical
product efﬁcacy. PRO instruments are often included in clinical
trials with the intention of collecting data to support claims made
about a medical product in the product label [3,4].
The US Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) have released guidelines for the assess-
ment of PROs. The FDA guidance has had a strong inﬂuence on
industry-funded PRO research since a draft was published in 2006
and ﬁnalized in 2009 [1]. This guidance provides an overview of
PRO use in the context of medical product development, as well
as guidance for developing and evaluating these instruments. A
brief section of the guidance discusses PRO instruments intended
for use with children and adolescents (Section III.G.1). This
section begins by stating that “issues related to the development
process for pediatric PRO instruments are similar to the issues
detailed for adults.” Then, the section continues by saying that
the use of PRO instruments in pediatric populations introduces
unique challenges that are not encountered in PRO research with
adults. Several challenges are mentioned, including age-related
vocabulary, comprehension of health concepts, the need to
determine the lower age limit at which children can provide
reliable and valid responses, and appropriate use of reports by
informants other than the patients themselves. No speciﬁc
recommendations, however, are provided for addressing these
challenges.Like the FDA, the EMA has provided recommendations for PRO
measurement, particularly with regard to the assessment of
health-related quality of life (HRQOL) [5]. The EMA guidance,
however, does not discuss the use of PRO instruments with
children and adolescents. In sum, there is limited available
guidance for research involving pediatric PRO assessment related
to medical product development.
Therefore, the purpose of the current task force report is to
recommend good practices for pediatric PRO research that is con-
ducted to inform regulatory decision making and support claims
made in medical product labeling. The recommendations in this
report are based on the consensus of an interdisciplinary group of
researchers who were assembled for a task force associated with the
International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). The good research practices are summarized in Figure 1.
The challenges of choosing, developing, and implementing
PRO instruments in children and adolescents have been reviewed
and discussed in many previous publications [6–22]. Several
published articles and book chapters have also provided lists
and reviews of generic and condition-speciﬁc PRO instruments
for children and adolescents [6,9,14,23–28]. The current task force
report differs from this previous work because of its speciﬁc focus
on pediatric PRO instruments in the context of medical product
development and labeling.
The recommendations in this report are based on published
research as much as possible. Pediatric PRO assessment, how-
ever, is a developing ﬁeld of research, and empirical evidence is
limited for some important areas of instrument design, develop-
ment, validation, and implementation. Therefore, it is not cur-
rently possible to provide deﬁnitive recommendations for some
of the issues discussed in the current report. In these situations,
this task force report discusses the factors to consider when
making decisions about the design and use of PRO instruments
for children and adolescents. In addition, this report highlights
areas in which further research is needed to advance the ﬁeld of
pediatric PRO assessment.
Good Research Practices Comments and Recommendations 
1. Consider Developmental 
Differences and Determine 
Age-Based Criteria for 
PRO Administration  
• Four age groups are discussed.  These age groups should be used as 
a starting point when making decisions.  It is not possible to provide 
age cutoffs that will fit every situation.  Specific age cutoffs should be 
determined individually for each PRO instrument and tested with 
cognitive interviews in each new target population.   
• Less than 5 years old: No clear evidence of reliability or validity of 
child-report measures 
• 5 to 7 years old: Child-report is possible, but reliability and validity are 
often questionable 
• 8 to 11 years old: Reliability and validity of child-report improves 
• 12 to 18 years old: Self-report is preferred 
2. Establish Content Validity 
of Pediatric PRO 
Instruments 
• Children and adolescents can be effective content experts.  
• In most cases, children should be included in qualitative research 
performed to establish content validity of pediatric PROs. 
• Cognitive interviews should be conducted with the intended 
respondent.  Children should be interviewed for child-report 
instruments, and parents should be interviewed for parent-report 
instruments. 
• Content validity should be demonstrated within narrow age groupings. 
3. Determine Whether an 
Informant-Reported 
Outcome Instrument is 
Necessary 
• Informant-reported outcomes include both proxy and observational 
measures. 
• When children in the target age range are capable of completing a 
PRO instrument independently, a child-reported measure should be 
used. 
• Second, when children in the target age range are not capable of 
completing a PRO measure, an informant-reported measure may be 
used.   
• Informant-reported measures should assess observable content as
much as possible.  
4. Ensure that the Instrument 
is Designed and Formatted 
Appropriately for the 
Target Age Group 
• Health-related vocabulary and reading level 
• Response scale  
• Recall period 
• Length of instrument 
• Pictorial representations 
• Formatting 
• Administration approaches 
• Electronic data collection (ePRO) 
5. Consider Cross-Cultural 
Issues 
• Content validity and measurement approach of a pediatric PRO 
instrument will need to be re-examined within each new culture.   
Fig. 1 – Good research practices discussed in this Task Force Report.
PRO, patient-reported outcome.
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Good Research Practice 1: Consider Developmental Differences
and Determine Age-Based Criteria for PRO Administration
The pediatric PRO literature has frequently focused on ques-
tions of developmental differences and age-related cutoffs[16,21,29,30]. For example, at what age can children begin to
report their health status, at what age are their responses
reliable, and when can children respond to items addressing
more abstract constructs? This task force group does not think
that it is possible to provide age cutoffs that will apply in all
situations. For any individual study or PRO measure, the answer
to these age-related questions will depend on a range of factors,
including the concept being assessed, the format of the instru-
ment, the level of independence required of child respondents
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measures), and characteristics of the population of interest (e.g.,
medical or psychiatric condition). Determination of age cutoffs is
further complicated by the substantial cognitive and develop-
mental variability within any particular age group, as well as
possible gender differences in perceptions and management of
medical conditions [31].
Despite these challenges, it is possible to offer guidance
regarding the abilities of children in various age ranges on the
basis of research in the areas of psychometrics and cognitive
development. While no age cutoffs will be appropriate for all PRO
instruments, it is necessary to discuss general age ranges to
summarize the literature and provide practical recommenda-
tions. This task force proposes that pediatric samples can be
categorized into four general age groups with regard to PRO
assessment for use in medical product evaluation, but these
age groups should be used only as a starting point when making
decisions. Speciﬁc age cutoffs should be determined individually
for each PRO instrument, and age ranges for a PRO instrument
should be tested with cognitive interviews whenever the instru-
ment is applied in a new target population.
Furthermore, as stated above, children within each age group
are likely to vary in their ability to reliably complete question-
naires. Researchers will need to remain aware of this variability
during data collection. While some studies rely on the judgment
of interviewers or data collection staff to determine whether
individual children can complete the study, a more standardized
approach is to screen for children’s ability to complete PRO
measures. For example, one recent study assessed the reading
level of every child with the American Guidance Service (AGS)
Reading Level Indicator [32]. Children who demonstrated reading
ability at or above the fourth-grade level were offered the option
of completing the study measure with a written mode of admin-
istration. For children scoring below the fourth-grade reading
level, the study measure was administered by an interviewer.
This screening approach is based on the idea that each child’s
ability, rather than numerical age, should determine if and how a
PRO measure should be administered. This task force encourages
further research on ways to screen for PRO instrument comple-
tion skills and address the variability within age groups.
It should also be noted that there is no clear consensus on
deﬁnitions of childhood or adolescence. Deﬁnitions vary by
culture and governmental organization. The deﬁnition adopted
by the World Health Organization [33] was originally provided by
the United Nations’ Convention on the Rights of the Child, Article
1: “A child means every human being below the age of 18” [34].
The Centers for Disease Control and Prevention has cited this
deﬁnition at least once [35], but a different Centers for Disease
Control and Prevention document has focused on a broader
group including individuals up to 19 years old [36]. The older
part of this range, beginning at approximately age 12 or 13 years,
is usually labeled as “adolescence” [37,38]. While acknowledging
that these deﬁnitions are ﬂuid and variable, this task force is
focused primarily on the age range of 0 to 18 years. In the current
report, the term “adolescence” refers to individuals ranging from
roughly 12 to 18 years old, while the term “younger children”
generally refers to those aged below 8 years.Age group 1 (younger than 5 years old)
The ﬁrst age category begins at birth and includes infants,
toddlers, and preschoolers. Although self-report instruments
have been designed to be completed by children younger than 5
years, there is no clear evidence of reliability or validity of self-
report measures in this age group [39]. Therefore, the assessment
of health status in this youngest age range must rely on clinical
measures and observational reports of parents or other adults.Age group 2 (5–7 years old)
The second age category consists of younger children ranging
from age 5 to 7 years. Generic and condition-speciﬁc self-report
measures are available for assessing the health status, includ-
ing symptoms and HRQOL, of children in this age range
[9,10,14,24,27,28,40]. Some researchers have advocated for direct
assessment of the child’s perspective beginning in this age range
[8,30,41], and there are some reports of acceptable psychometric
data as low as age 5 years. For example, 5-year-old children
completing the Pediatric Quality of Life Questionnaire (PedsQL), a
widely used generic HRQOL measure, yielded minimal missing
data (2.8%) and good internal consistency reliability with a
Cronbach’s alpha of 0.86 for the total score based on all 23 items
[21]. Results of other studies, however, have contradicted this
ﬁnding, with reports of less encouraging psychometric results. In
the validation of the child-report version of the Child Health and
Illness Proﬁle (CHIP-CE), internal consistency and test-retest
reliability for children aged 6 to 7 years were below a generally
accepted range (i.e., ≥0.70) for three of ﬁve subscales (Cronbach’s
alphas for multiple subscales ranged from 0.64 to 0.83; intraclass
correlation coefﬁcients [ICCs] ¼ 0.35–0.69), but these reliability
statistics were notably better in the 8 to 11 years age group
(Cronbach’s alphas ¼ 0.72–0.85; ICCs ¼ 0.71–0.80) [42]. Similarly,
developers of a self-report measure for children with epilepsy
reported an increase in test-retest reliability from children aged 6
to 7 years (ICCs ¼ 0.18–0.52) to children aged 8 to 15 years (ICCs ¼
0.59–0.69) [43]. Furthermore, a review of 53 health-related self-
report measures for children up to age 8 years found that only
51% of the measures met minimum standards for internal
consistency reliability (i.e., Cronbach’s alpha ¼ 0.70), and only
23% of the measures met standards for test-retest reliability (i.e.,
ICC ¼ 0.70) [24]. Based on available data from young children,
test-retest reliability seems to be particularly problematic,
whereas internal consistency reliability tends to be closer to
generally accepted standards.
In addition to concerns about reliability, some ﬁndings suggest
that many children aged 5 to 6 years may not use the full range of
a typical ﬁve-point Likert scale. Instead, they may rely more on
responses at the middle and/or extreme ends of the scale, as if
they were responding on a three-point scale [19,44]. Health-
related vocabulary may also be limited in children of this age
range. A cognitive interview study found that children’s compre-
hension of terms commonly used in health status questionnaires
(e.g., nervous, energy, and pain) tends to be limited at age 5 years,
but gradually increases from ages 6 to 8 years (Fig. 2) [19].
Research on cognitive processing capabilities suggests that
PRO data reported by children in this age range may be useful for
assessment of some concepts but should be interpreted with
caution [29,45]. Children aged 5 to 7 years typically understand
basic ideas of feeling healthy/unhealthy or good/bad, and they
can usually apply these ideas to themselves, often with some
speciﬁcity. It has also been suggested, however, that children in
this age range may have uneven cognitive capacities (i.e., strong
abilities in one cognitive domain such as word recognition, but
not in another area such as attention). Furthermore, some
children may be slow, inefﬁcient, or error-prone in choosing the
response option that best represents their perspective [29,45].
In sum, although self-report measures may be useful for
gathering health-related information among children aged 5 to 7
years, previous research raises questions regarding the reliability
and accuracy of their responses. For PRO measures to be consid-
ered acceptable for regulatory decision making, they will need to
demonstrate content validity and acceptable psychometric prop-
erties in the target age range, which may be challenging in this
age group. The likelihood of demonstrating acceptable measure-
ment properties in children aged 5 to 7 years may be maximized
by using or designing PRO measures that assess simple concepts
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Fig. 2 – Age differences in children’s understanding of health-related terms.
Findings reported by Qual Life Res, 10, Rebok G, Riley A, Forrest C, et al., Elementary school-aged children's reports of their
health: a cognitive interviewing study, 59–70, 2001. With kind permission from Springer Science and Business Media.
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response options than do measures for older children. If it is not
possible to demonstrate adequate measurement properties in this
age group, informant-reported outcome measures completed by
parents or other adults may be used (see Good Research Practice 3
of this task force report). We encourage further research on child-
reported PRO measures in this age group in the hope that child-
ren’s experience and subjective perspective may be considered in
regulatory decision making.
Age group 3 (8–11 years old)
The third age group consists of older children, ranging from
roughly age 8 years to age 11 years. Children’s ability to inde-
pendently complete health status measures appears to improve
in this age range. As described earlier in the discussion of age
group 2, several studies have found increased reliability, com-
prehension of health vocabulary, and understanding of Likert
scales in samples of children aged 8 years and older than in
samples of younger children [19,42,43]. Self-reports of children in
this older age range frequently meet generally accepted stand-
ards for reliability on both generic and condition-speciﬁc meas-
ures [21,27,46].
Results of a recent cognitive interview study conducted by the
Patient Reported Outcomes Measurement Information System
(PROMIS) pediatrics group demonstrate some of the relevant
skills of children in this age group [47]. The sample in this
qualitative study focusing on a pediatric item bank included 24
children aged 8 or 9 years. Like the adolescents, children in this
age group were able to comprehend the majority of items,
response options, directions, and recall period, while identifying
language that was difﬁcult to understand.Research on children’s cognitive development provides fur-
ther support for the use of self-report methodology for children
beginning in the 8 to 11 year age range [29]. At this point of
development, the cognitive capacities needed to respond to
health questionnaires have developed in most children. These
capacities include 1) an understanding of health concepts; 2) self-
regulatory abilities including sustaining effort, minimizing frus-
tration, and avoiding distractions; and 3) cognitive processing
capacities including the ability to understand the task, keep the
question in working memory long enough to respond, evaluate
how the question applies to oneself, evaluate the differences
between response options, and choose the optimal response [29].
In sum, there is a growing body of research supporting the
feasibility and reliability of self-reports in children aged 8 to 11
years. Therefore, it may be acceptable to use self-report data from
this age group in research conducted for medical product evalua-
tion. As with all PRO end points, careful qualitative research will
be required to convincingly demonstrate that children in this age
range understand the PRO measure as intended.
Age group 4 (12–18 years old)
The fourth age group consists of adolescents, beginning at
approximately age 12 years. Most adolescent PROs are designed
and validated for respondents up to ages 16, 17, or 18 years [27].
Adolescent self-report measures do not appear to face greater
challenges meeting generally accepted psychometric standards
than do adult measures [21,28,46]. The primary challenge in
developing PRO measures for adolescents, however, is capturing
content that is relevant to this age group. Although items assess-
ing symptoms may be similar to those in adult measures, devel-
opers designing instruments to assess symptom impact or
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emotional aspects of this developmental stage. This was illus-
trated by a qualitative study that used focus groups and inter-
views with 12- to 18-year-olds to elicit concepts for a quality-of-
life measure [48]. The resulting conceptual model highlights the
uniqueness of adolescence, with a wide range of relevant concepts
such as adult support, freedom, peer relations, being oneself,
spirituality, life satisfaction, monetary resources, view of the
future, and education. Many of these domains are more sophis-
ticated than concepts that may be included in a measure aimed at
children below age 12 years. Yet, domains such as peer relations,
view of the future, and education may include content different
from that of adult PRO measures. Thus, many adult measures are
unlikely to be appropriate for adolescents. Determining appropri-
ate item content for this age group is further complicated by the
heterogeneity across this age span. For example, content that is
relevant to an 18-year-old may not be relevant to a 12-year-old. In
sum, adolescent self-report measures frequently demonstrate the
psychometric properties necessary to be used as a key study end
point in clinical trials. Qualitative research, however, will also be
required to demonstrate that an individual instrument has con-
tent validity speciﬁc to the target age group.
Individuals older than 18 years are generally administered
PROs that were designed for use across all ages of adult samples.
However, it may be useful to consider the relevance of previously
validated instruments to young adults who may have distinct
developmental characteristics. Researchers have suggested that
the 20s could be viewed as a stage of life called “emerging
adulthood” [49,50]. This phase of life appears to be associated
with unique challenges with regard to the level of independence,
personal identity, career development, and relationships.
Research on development and adaptation during this phase will
be published in a new scientiﬁc journal titled Emerging Adulthood,
which is launching in 2013. Some adult PRO measures may
require qualitative research to ensure that all items have content
validity in this transitional age group.
In sum, when developing new PRO instruments or using
existing instruments for research involving medical product
evaluation, it is critical to demonstrate the age appropriateness
of the instrument for the target population. Age appropriateness
of a PRO should be documented with a combination of qualitative
and quantitative research. First, cognitive interviews should be
conducted to examine that all aspects of the instrument are
appropriate for the target age group. These interviews should
assess the respondents’ perspectives on the instrument’s
vocabulary level, item content, recall period, response options,
instructions, comprehensiveness, relevance, and clarity. This
qualitative research should be conducted with an adequate
sample size at the upper and lower bounds of the target age
range to ensure that there are sufﬁcient data to support the
selected age cutoffs. Subsequently, quantitative research can be
conducted to examine the instrument’s psychometric properties
in a sample matching the intended age range of children in
planned clinical trials.
Good Research Practice 2: Establish Content Validity of
Pediatric PRO Instruments
Children as content experts
In recent years, establishing content validity has been empha-
sized as a critical step of PRO instrument development and
validation [1,51,52]. Deﬁnitions of content validity vary [53], but
the deﬁnition proposed by a previous ISPOR task force appears
consistent with most of the literature, including the FDA guid-
ance: “The extent to which an instrument contains the relevant
and important aspects of the concept it intends to measure” [54].
There is also a consensus that content validity is primarilyestablished through qualitative research that includes direct
input from the target population.
This qualitative work, which has previously been described in
detail, generally proceeds in two sequential steps: concept elic-
itation and cognitive interviews [1,55,56]. First, concept elicitation
interviews or focus groups with individuals from the target patient
population are conducted to inform item generation [51]. Semi-
structured interview and focus group discussion guides are usually
drafted on the basis of information gathered during literature
review and clinician interviews. In the concept elicitation phase,
patients help identify concepts and wording that will shape the
items of a PRO measure. When conducting concept elicitation
work for pediatric PRO measures, it is particularly important to
identify the speciﬁc language patients use to describe their illness
and treatment because children and adolescents may use different
words than do adults. Information gathered during concept
elicitation should also be used to support the instrument’s con-
ceptual framework, which is a diagram illustrating relationships
between items, domains, and concepts measured by the instru-
ment [1]. It is important that the conceptual framework of a
pediatric instrument be speciﬁcally relevant to the target age
group, rather than a replication or rewording of a conceptual
framework previously developed for an adult measure [14].
After drafting an instrument, the second step is to conduct
cognitive interviews to assess and reﬁne the draft instrument on
the basis of patients’ perceptions of the measure’s relevance, clarity,
and comprehensiveness [52,57]. These qualitative research proce-
dures are considered necessary for establishing content validity,
which cannot be demonstrated via quantitative psychometric
analyses. The FDA guidance provides detailed recommendations
regarding methods for establishing content validity, but it does not
mention conceptual or methodological challenges unique to the
assessment of content validity for pediatric measures.
Despite the FDA’s encouragement to provide documentation of
content validity based on patient input [1], researchers may still be
hesitant to develop PRO instruments on the basis of direct input
from children. Content validity of child- and parent-reported
pediatric measures has often been supported by input from
parents or clinical experts rather than the children themselves
[58–61]. A growing body of research, however, has indicated that
children and adolescents can be effective content experts [62–65].
For example, one study examined the use of adolescents as
“experiential experts” when establishing content validity, and the
authors concluded that the adolescents’ input resulted in greater
relevance of the PRO for the target population [66]. Clearly, there
are situations when it is not feasible to obtain the child’s perspec-
tive, such as when the target population is too young or cognitively
impaired to read, comprehend, or respond to questions about
health status [67,68]. When children, however, are able to discuss
their health status, they may have a unique perspective based on
personal experience that is unknown to clinicians or parents.
As with adult PROs, assessment of the child’s perspective
during concept elicitation and item generation is critical for
ensuring that a pediatric PRO measure is relevant and compre-
hensive to the target population. Furthermore, there are some
aspects of symptom experience and impact that are known only
to patients themselves [2]. Therefore, we recommend either
including children in qualitative research performed to establish
content validity of pediatric PROs or providing justiﬁcation for
excluding children from this research. Qualitative data from
children should be considered along with parent, clinician, and/
or expert reports when drafting and reﬁning measures.The central role of children’s context
The basic principles and methodology of content validity are the
same for pediatric PROs as for adult PROs. The assessment of
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with unique conceptual issues and methodological challenges
that do not arise when developing measures for adult popula-
tions. First, the early phases of establishing content validity focus
on identifying the target concept of the PRO measure and the
“content” of the items. When conducting research to elicit con-
cepts and items for a pediatric measure, it is important to consider
the central role of context in child development. Children are
embedded within multiple social contexts that may be different
from those of adults. These contexts include the family, the
child’s peer group, the classroom, extracurricular activities, and
the community [16,69]. The impact of disease and treatment, as
well as the relevance of individual symptoms, may be different
within each of these contexts. For example, there may be
symptoms that have a relatively minor impact on adults, but
limit a child’s ability to participate in athletics or daily activities
with peers. Thus, when developing pediatric PRO instruments,
researchers must consider the relevance and impact of symptoms
and treatment within these contexts. Although parents may have
insight into their children’s health experiences at home, only the
children themselves are likely to have a broad perspective span-
ning multiple settings and social groups. Therefore, to ensure that
an instrument adequately assesses all important aspects of a
condition and its treatment, the child’s perspective should be
considered when establishing content validity.Concept elicitation and item generation
Procedures for concept elicitation and item generation have
previously been described in detail [51]. Concept elicitation
research with children, however, raises additional methodolog-
ical issues that are not encountered when conducting qualitative
research with adult samples. First, we recommend conducting
this qualitative research with several types of respondents,
including the children themselves. As previously stated, children
should be included in the early stages of establishing content
validity whenever possible, particularly when developing a child-
report instrument. Clinicians, including pediatricians, pediatric
nurses, and other medical staff, are another important source of
information. When developing a pediatric PRO, it is necessary to
query clinicians who have direct experience treating children in
addition to experience with the relevant medical condition.
Parents or other primary caregivers are also likely to be a critical
source of information, particularly when developing measures for
younger children or when developing parent-reported measures.
Finally, when assessing conditions such as attention-deﬁcit/
hyperactivity disorder that may be particularly relevant in the
school setting, teachers may have unique insight into children’s
symptoms and the impact on social and academic functioning. In
sum, content validity of pediatric PROs should be based on
qualitative data from patients as well as other informants such
as parents and clinicians.
Concept elicitation research may be conducted via individual
interviews or focus groups, and these two approaches have
different advantages [51]. For example, focus groups allow
researchers to reach many patients at once, while patients can
use the ideas of other respondents as cues to express their own
views. With adult patients, focus groups are sometimes recom-
mended so that participants can respond to each other, thus
leading to richer information about the patient experience [56].
Some challenges inherent to the group process, however, may
arise more with children or adolescents than with adults. For
example, some younger children may become distracted to a
greater extent than do older children or adults. Children’s
reports may also be inﬂuenced by their peers’ statements or a
social desirability bias, resulting in a less accurate presentation
of their own symptoms and experience. Furthermore, because ofthe complex social pressures of childhood and adolescence,
pediatric respondents may be reluctant to speak openly in group
discussion.
When conducting focus groups, researchers can take steps to
encourage children and adolescents to share accurate and
honest health-related information. For example, although many
adult health issues can be discussed in mixed gender groups,
children and adolescents may be more comfortable and forth-
coming in single gender groups, particularly when discussing
sensitive topics such as sexual activity or adolescent maturation
issues. Researchers should also consider whether the medical
condition of interest may cause shame, embarrassment, or self-
consciousness, which could be more inhibiting for children and
adolescents than for adults. For example, adolescents may resist
discussing their difﬁculties with obesity in the presence of peers,
and one qualitative study reported that children with foot and
ankle problems expressed self-consciousness regarding the
appearance of their shoes, which were different from those of
other children [62]. Adults may also be hesitant to discuss some
topics in the presence of other patients, but this hesitance or
embarrassment can be particularly challenging with children
and adolescents.
Although individual interviews do not beneﬁt from the group
dynamic of focus groups, interviews may be used to gather more
detailed information about an individual’s experience. Interviews
may be more effective than focus groups for sensitive topics that
may be uncomfortable to discuss in front of others. In addition,
unlike focus group results, data from individual interviews can be
used to accurately represent each individual respondent when
creating a saturation table or grid to support content validity (see
previous ISPOR task force report for details regarding saturation
tables; Patrick et al. [51]). In contrast, when analyzing focus group
data, it is often difﬁcult to determine precise numbers of patients
who reported a speciﬁc symptom or impact.
This task force recommends that child concept elicitation inter-
views conducted to inform the development of child-reported PROs
should be performed without parents whenever possible. The
purpose of these interviews is to understand the child’s own
subjective perspective and experience, and parent participation in
the child interview session could introduce a risk of obscuring the
child’s perspective. For example, some parents may impose their
own perspective or be tempted to answer questions on behalf of
their children, rather than letting children speak for themselves.
Furthermore, if children know a parent is listening, they may feel
inhibited when discussing certain topics, or they may be motivated
to please their parents rather than responding honestly. For most
child-reported PRO measures, the parent’s perspective is likely to be
useful for eliciting concepts and generating items. This task force
recommends that parents be interviewed separately from children
to assess the parents’ views without having an impact on informa-
tion gathered during the child interview.
There are some context-speciﬁc exceptions to the recommen-
dation that child concept elicitation interviews be conducted
without a parent present. If a child is not comfortable being
interviewed without a parent present, researchers should allow
the parent to join the child in the interview room, but the parent
should be discouraged from actively participating in the inter-
view process. Parents may also be asked to sit behind the child so
that the parent cannot make eye contact with the child or
inadvertently inﬂuence the child’s responses. In addition, there
are rare situations when a questionnaire is designed to be
administered to a parent-child dyad to assess a shared medical
experience [70]. In these situations when the shared perspective
is of interest, it may be useful to develop the questionnaire based
on dyadic rather than individual concept elicitation interviews. It
should also be noted that there is some support for a parent-child
dyad approach to assessment of the child’s HRQOL, as opposed to
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Some innovative studies have suggested that trained inter-
viewers can elicit reliable and valid responses from parent-child
dyads, while possibly enhancing accuracy and minimizing
response bias and missing data that can occur when children
complete measures or interviews independently [71,72]. While
these thought-provoking ﬁndings clearly merit consideration and
future research, this task force believes that the risks of parent
participation in children’s concept elicitation interviews out-
weigh the potential beneﬁts except in rare circumstances. There-
fore, it is recommended that children’s concept elicitation
interviews be conducted without parent participation (or partic-
ipation of other adults such as teachers) whenever possible to
ensure that the child’s responses are not biased or inhibited by
the parent’s opinions and presence.
Given the challenges of conducting focus groups with children
and adolescents, researchers may choose to conduct both focus
groups and individual interviews. This combined approach takes
advantage of the rich information that may arise from the group
dynamic in a focus group, while conﬁrming that individual
interviews do not yield different concepts. If focus groups appear
to be unproductive for speciﬁc medical conditions within certain
age groups, researchers may need to continue qualitative
research using only individual interviews.
Designing a productive concept elicitation interview or focus
group for children is often challenging. At the beginning of inter-
views/focus groups, the interviewer should speak with the chil-
dren to conﬁrm that they understand the purpose of the interview.
In addition, direct inquiries regarding symptoms and their impact
can be productive only if they are worded and presented in a way
children can understand. One approach is to begin with general
questions and gradually proceed to more focused queries. For
example, initial questions may be most effective if they are
simple, open-ended, and easy to answer, while conveying an
interest in the child’s life (e.g., “Can you tell me about what you
do at home after school?”). Follow-up questions could then assess
the impact of health and illness on activities and other topics
raised by the child in response to the introductory questions.
Subsequent questions can gradually focus more speciﬁcally on the
child’s health and related limitations. During the concept elicita-
tion process, researchers should remain open to improvements in
the interview design, and the interview guide may need to be
revised on the basis of the ﬁrst few interviews.
Some researchers have suggested creative activities to help
children provide useful information during the interviews or
focus groups. One interesting example is the focus group study
conducted to elicit concepts for the Oxford Ankle Foot Question-
naire, which assesses disability associated with children’s foot
and ankle problems [62]. In one part of these groups, children
participated in a “life-mapping” activity in which they were asked
to consider a day in the life of a hypothetical child with a foot or
ankle problem, including issues related to various times of day
and multiple settings (e.g., in the morning, at school, at home,
weekends, and holidays). Children were asked to name this
hypothetical child and work together to describe problems that
this child encountered in each setting. The researchers asked the
children to discuss a hypothetical child to help them discuss
potentially sensitive issues, such as bullying, without directly
asking about difﬁcult personal experiences. As another strategy
for making the children feel comfortable, these focus groups
began with a warm-up activity involving discussion of a non-
threatening topic. This activity appeared to have beneﬁcial
effects on children’s willingness to speak freely in the group.
The authors concluded that focus groups involving creative child-
centered activities elicited useful information regarding the
effects of childhood foot and ankle problems, even with most of
the children in the youngest age group (5–7 years old).Another qualitative study used an innovative approach
involving drawing to elicit descriptions of restless legs syndrome
and its impact in children aged 6 to 17 years [73]. Children were
asked, “Do you think you could draw me a picture of how it feels
when you get that feeling in your legs on this piece of paper?”
After completing the drawing, children were requested to “Tell
me about your picture.” The drawings appeared to facilitate
communication and help the children describe their symptoms
verbally. These results suggest that drawing could be a poten-
tially useful approach in concept elicitation interviews or focus
groups with children.Cognitive interviews
After drafting a PRO instrument, it is standard practice to conduct
interviews with respondents from the target population to
provide additional evidence of content validity by conﬁrming
that patients understand the items and believe the measure
adequately represents the concept of interest [1,52,54]. These
interviews have frequently been called “cognitive debrieﬁng
interviews,” but they are more recently referred to as “cognitive
interviews.” For pediatric instruments, we recommend that
cognitive interviews be conducted with the intended respondent.
That is, children should be interviewed regarding child-report
instruments, and parents should be interviewed regarding parent
proxy or observational instruments.
In cognitive interviews for adult instruments, respondents
in the target population are asked about the clarity, comprehen-
sibility, comprehensiveness, and relevance of items. Cognitive
interviews with children can follow the same general interview
procedures as those previously described for adults [52,55,56,74],
but it is also useful to probe further to ensure that the interviewer
truly understands the child’s level of comprehension. For exam-
ple, after a child has responded to an item, the child may be
asked to explain how he or she selected the answer. Other useful
questions about individual items may include “what does this
question mean to you?” and “what is this question asking you to
do?” The child’s responses may reveal that the child had
interpreted the question differently than the researcher had
initially thought. A useful approach for characterizing the types
of difﬁculties respondents may have with items has been pre-
sented by Knaﬂ et al. [74].
The developmental appropriateness of a PRO instrument is a
central issue to be considered during the cognitive interview
process. The FDA guidance [1] recommends “instrument develop-
ment within fairly narrow age groupings.” This recommendation is
particularly important for cognitive interviews. Even if a PRO
instrument has demonstrated content validity in one age range,
content validity in other age ranges cannot be assumed. Although
the content needed to represent a given construct may be similar
across age groups, developmental differences in the understanding
of particular items and in the relevance of each item may affect
content validity. For example, vocabulary that is commonly used
by children of one age group to describe their symptoms may be
too sophisticated for slightly younger children. Furthermore, the
content of some items may not be equally relevant across all child
age groups, particularly items assessing social or activity-related
impact of symptoms. A previous ISPOR task force has provided
detailed recommendations on cognitive interviewing methods for
evaluating other aspects of PRO instruments such as instructions,
recall period, response options, instrument formatting, instrument
length, and mode of administration [52]. When conducting these
interviews for child-reported instruments, it is important to
evaluate each of these characteristics within narrow age groupings
to ensure that all aspects of the PRO measure are appropriate for
the full age range of the intended population. In sum, whether
developing a new instrument or using a preexisting instrument
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tent validity, clarity, comprehensibility, and age appropriateness of
a PRO instrument throughout the speciﬁc age range matching the
intended use of the instrument.
Throughout a cognitive interview, children may have more
difﬁculty than adults in understanding their role as content
experts in the questionnaire development process. For example,
some children may focus on their own responses, rather than the
more abstract task of reviewing the questionnaire for content and
clarity [64]. Thus, clear explanation of the questionnaire review
process should be provided at the beginning of each interview,
and interviewers should be trained to reorient the child to the
task of reviewing the questionnaire whenever necessary.
Although there are few published examples of cognitive
interview studies conducted with children, some studies have
reported encouraging results. In the process of developing a
pediatric item bank, the PROMIS pediatrics group conducted
cognitive interviews with 77 children ranging from ages 8 to 17
years [47]. Children in all age ranges were able to contribute
useful information regarding their own health and the items
themselves. The authors also concluded that children offered a
perspective on items’ comprehensibility, as the younger children
helped to identify several terms that were difﬁcult to understand.
A cognitive interview study of the PedsQL Diabetes Module also
included interviews with children as young as 8 years [75]. The
version of the questionnaire for 8- to 12-year-old children was
edited on the basis of children’s input during these cognitive
interviews.
Good Research Practice 3: Determine Whether an Informant-
Reported Outcome Instrument Is Necessary
When assessing younger children’s health status, it is common to
assess the perspective of informants instead of the children
themselves. Informant-reported outcome measures may be nec-
essary when children are not able to complete PRO measures
reliably on their own because of their developmental stage,
illness severity, language ability, or cognitive functioning
[16,29,76,77]. This task force uses the term informant to refer to
people other than the child who provide information related to
the child. The informant is most frequently the child’s parent, but
measures may also be completed by other adults such as
clinicians, teachers, and other caregivers. Although measures
completed by informants are not actually “patient-reported,” this
task force provides recommendations for the use of informant
measures because of their frequent use in pediatric assessment.
Before providing recommendations, it is necessary to deﬁne
some relevant terminology. Informant-reported measures can be
divided into two broad categories on the basis of the content of
the items in the method of assessment: proxy and observational.
These two categories can be further divided into subcategories, as
illustrated in Figure 3. Proxy items require the informant to make
inferences about the child’s subjective experience. Many parent-
report forms include proxy items asking parents to report their
child’s experiences of subjective constructs, such as emotional
state, level of satisfaction, or pain severity [78–80]. Proxy items
may also ask an informant to report impressions of how a child
would answer speciﬁc questions. One study focusing on care-
givers of adult patients found that items requiring informants to
respond as if they were the patient may have a stronger
correlation with patient reports than may items asking inform-
ants about patients’ subjective experience [81]. In pediatric
research, proxy items may yield useful data as parents typically
have a valuable understanding of their children based on many
important experiences. Furthermore, the parents’ perspective is
important because parents typically make health care decisions
for children and adolescents.The literature on proxy reporting has often focused on the
degree of agreement between parent and child reports. This
research has found mixed results, with some studies reporting
strong agreement [82–85], while other studies have highlighted
discrepancies between parent and child perspectives [86–92]. The
degree of agreement appears to depend on a complex combina-
tion of factors, including the parent’s health [86,91,93], parental
distress [94], the child’s age [21,86,95], the child’s health
[25,90,93,96], the statistical method for assessing agreement
[86,93], and the domain being assessed [25,93]. Given these
ﬁndings, most researchers recognize that parent reports cannot
be accepted as a consistently accurate representation of child-
ren’s subjective health experiences. Although parents can pro-
vide a useful perspective on their children’s health status, proxy-
report items inherently require the respondent to make infer-
ences about another person’s subjective experience, and these
inferences are not necessarily equivalent to the person’s actual
experience.
Because of these challenges, the FDA PRO guidance [1]
discourages proxy-reported outcome measures for pediatric pop-
ulations in the context of research on medical product evalua-
tion. The guidance, however, acknowledges that there are
pediatric populations, such as very young children, who will
not be able to report their own health status. In these situations
when it is necessary to gather information from informants, the
FDA recommends that measures should be observational rather
than proxy. The guidance document states that these “observer
reports … include only those events or behaviors that can be
observed.” To illustrate this concept, the FDA guidance provides
one example: “observers cannot validly report an infant’s pain
intensity but can report infant behavior thought to be caused by
pain.” Speciﬁc examples of observable signs of children’s symp-
toms are provided in the FDA guidance [97] for the clinical
development of drugs for the treatment of acute bacterial otitis
media, an inﬂammation of the middle ear caused by a bacterial
pathogen. For infants and young children who cannot articulate
their symptoms, the guidance recommends assessing adult
reports of observable signs such as ear tugging, ear rubbing,
fussiness, and decreased appetite.
Proxy-report measures have yielded important information
about child health and functioning, and this task force encour-
ages future research involving parent proxy measures. Still, this
task force agrees with the FDA recommendation that proxy
measures should be avoided in research conducted for use in
the regulatory context. Data contributing to regulatory decision
making and medical product labeling must be as unambiguous as
possible. Results based on proxy measures are associated with an
unavoidable uncertainty, as indicated by frequent discrepancy
between informant and child perspectives.
This task force also supports the FDA’s recommendation for
the use of observational measures whenever it is necessary to
use informant reports in research conducted for medical product
labeling. The discrepancy between parent and child reports has
generally been shown to be greatest for nonobservable subjective
domains, such as pain and emotional issues [9,25,98,99]. In
contrast, these studies have frequently found stronger concord-
ance between parent and child reports for more observable,
objective domains such as physical functioning. These ﬁndings
suggest that parent-report measures are likely to be most
accurate and reliable when the items focus on observational
content. Two examples of observational measures designed for
the assessment of young children include the Keller Index of
Nausea, which was designed for completion by pediatric nurses
[100], and the parent-completed Revised Infant Gastroesophageal
Reﬂux Questionnaire [101]. As illustrated in Figure 3, observatio-
nal measures can focus on momentary assessment of the child’s
behavior completed at the time of observation or general
Informant Reported Outcome 
Measures:  
Measures completed by 
informants rather than children 
themselves (The informant is 
most frequently a parent, but 
may also be a clinician, teacher, 
other caregiver, or other adult.)
Proxy Measures:
Items involving 
interpretation, requiring 
informants to make 
inferences about the 
child's subjective 
experience
Impressions of 
Child’s
Experience: Items 
asking informants 
to report their 
impressions of a 
child’s subjective 
experiences
Proxy Momentary 
Assessment:
Items asking informants 
to report their 
impressions of a child’s 
subjective experiences, 
completed while directly 
observing the child 
Assumptions of 
Child’s
Responses: Items 
asking informants 
how they think a 
child would 
respond to specific 
questions
Observational
Measures:
Items assessing directly 
observed behavior, 
without interpretation or 
inference 
General 
Observations
(Behavior):
Items assessing the 
informant’s general 
observations of a 
child’s behavior, 
often within a 
specified time-period 
Observational
Momentary 
Assessment:
Items assessing 
observable
behavior, 
completed while 
directly observing 
the child
General Observations 
(Statements):
Items assessing the 
informant’s
observations of things 
the child has said, often 
within a specified time-
period 
Fig. 3 – Types of informant-reported outcome measures for pediatric assessment.
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period. Either of these two observational approaches may be
appropriate for research intended to support medical product
labeling. A third type of observational item, involving reports of
statements the child has made, is usually less desirable because
it depends on clarity of parent-child communication and accu-
racy of parents’ memory regarding their children’s statements.
Based on consideration of published literature and recent
regulatory developments, this task force can provide three
recommendations regarding the choice between child-reported
and informant-reported outcome measures in the regulatory
context. First, when children in the target age range are capable
of completing a PRO instrument independently, a child-reported
measure should be used (for discussion of developmental differ-
ences in ability to complete PRO measures, see the discussion of
Good Research Practice 1). In the regulatory context, a child-
reported measure is preferred because it is the most direct
assessment of the child’s experience of disease and treatment,
without any bias or interpretation that could stem from inform-
ants’ reports. To be considered capable of completing a PRO
instrument, children within a target age range must demonstrate
the ability to read a questionnaire, understand the relevant
concepts, and provide reliable and valid responses. Reading and
comprehension should be examined in cognitive interviews,
while reliability and validity of responses can be documented in
larger psychometric validation studies of PRO measures. Given
the developmental differences within any age group, there will
likely be some children who are not capable of completing a PRO
measure even when the great majority of their peers are capable.
Therefore, researchers may have to identify outliers and attend
to general trends within a target age group when determining
whether the age group should be considered capable of complet-
ing a particular PRO instrument.Second, when children in the target age range are not capable
of completing a PRO measure, an informant-reported measure
may be used. Third, when using an informant-reported measure,
all items in the instrument should assess observable content as
much as possible, rather than subjective aspects of the child’s
experience.
It should also be noted that there are situations when it may
be useful to have parents and children complete parallel forms of
the same instrument. Interpretation of data from two simulta-
neous sources, however, often raises challenges as discussed in
the “Conclusions and Recommendations for Future Research”
section of the current report.
Good Research Practice 4: Ensure that the Instrument Is
Designed and Formatted Appropriately for the Target Age
Group
Several review articles have discussed aspects of pediatric PRO
measure design and formatting that vary depending on the age of
the respondents [6,8,9,14–16,24,102]. Partly in response to the
emphasis on qualitative methods in the FDA PRO guidance, there
is also a growing body of research directly assessing the child’s
perspective on questionnaire design and formatting [19,47,
103,104]. These initial studies have yielded useful information,
and our understanding of questionnaire design and formatting
will continue to evolve as more pediatric cognitive interview
studies are published. Therefore, we encourage more qualitative
research focusing on ways to most effectively format and design
PRO measures.
The following sections discuss a range of factors that must be
considered to ensure that a PRO instrument is developmentally
appropriate for the age range of a pediatric sample. It is important
to consider these factors when developing a new instrument as
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a new age group. Speciﬁc age cutoffs for any aspect of instrument
design depend on numerous interrelated factors such as item
content and health-related characteristics of the target popula-
tion. Therefore, this section does not provide age cutoffs that will
apply in every situation. Instead, the purpose of this section is to
review aspects of instrument design and format that are likely to
differ among age groups, while providing recommendations based
on developmental trends reported in published studies.
Health-related vocabulary and reading level
It has frequently been noted that children’s health-related vocabu-
lary increases with age [15,16]. Findings reported by Rebok et al. [19]
illustrate this developmental trajectory. In this study, children’s
understanding of health-related terms was examined within four
age groups: ages 5, 6, 7, and 8 to 11 years (Fig. 2). For most of the
terms, the percentage of respondents with a poor understanding
decreased as the age increased. For example, 14.3% of 5-year-old
children have a poor understanding of the term “pain” compared
with 8.3% of 6-year-olds, 6.2% of 7-year-olds, and 0% of older
children. The percentages of poor understanding also decreased
with age for other health-related terms, such as “energy,” “healthy
enough,” “comfortable,” and “nervous.” Similar patterns of ﬁndings
have been observed in other pediatric samples [71].
Clearly, it is critical that the vocabulary and reading level of a
questionnaire are not more advanced than the linguistic abilities
of the target population. Instrument developers have long been
aware of this issue and have made efforts to simplify language
and concepts in versions of questionnaires designed speciﬁcally
for younger age groups [9,80,105]. One common approach is to
assess the reading level of a questionnaire, using readability
indices such as the Flesch-Kinkaid Grade Level score, and edit the
questionnaire until it is suitable for the target age range
[9,80,106,107]. In addition to vocabulary, factors contributing to
readability include syntax complexity, sentence length, and the
number of sentences per paragraph [14]. One strategy for devel-
oping a questionnaire with age-appropriate vocabulary is to
observe the language children use during concept elicitation
interviews and focus groups [51]. Then, this vocabulary derived
directly from children in the target age range can be incorporated
into the resulting instrument.
When a pediatric PRO measure is used in a regulatory sub-
mission, documentation that the vocabulary level is ﬁt for use in
the target age group is important. Age appropriateness of reading
level and vocabulary may be supported by readability index scores
and data from cognitive interviews in which respondents from the
target age group provide feedback on the comprehensibility of
items. Cognitive interviewing methodology was found to be an
effective approach for editing vocabulary of the PROMIS pediatric
item bank [47]. In this qualitative interview study with 77 children
and adolescents aged 8 to 17 years, cognitive interviews identiﬁed
several terms that were incomprehensible to some children within
this age group. Problematic terms included irritable (suggested
change: cranky), exhausted (suggested change: tired), furious
(suggested change: angry or mad), and social activities (suggested
change: activities with friends). Similar results were reported in a
study involving cognitive interviews focused on the PedsQL
Diabetes Module [75]. Children reported that several words were
difﬁcult. Therefore, the version of the questionnaire for 8- to 12-
year-old children was edited to include more age-appropriate
language. For example, “fatigue” was changed to “tiredness,” and
“irritable” was changed to “cranky or grumpy.”
Response scale
A review of health-related self-report measures for children aged
3 to 8 years found that Likert scales (i.e., scales with descriptorsalong a continuum) [108,109] were the most commonly used type
of response scale, appearing in 34 of the 53 measures identiﬁed
for use in this age group [24]. Other types of scales included
graphic representations, facial expressions, and a visual analogue
scale, which is very rarely used in pediatric measures and
frequently misunderstood by young children [110]. One study of
120 children aged 6 to 18 years found that children preferred
Likert scales over visual analogue scales and numeric 10-point
rating scales, reporting that Likert scales were easier to complete
[104]. Furthermore, the cognitive interview study examining the
PROMIS pediatric item bank found that even the youngest
children in the sample (i.e., 8 years old) had no apparent difﬁculty
understanding the response options of a ﬁve-point Likert scale
[47). In addition, a Delphi panel convened for the development of
a child HRQOL measure yielded a consensus, with 94.1% of the
respondents indicating that Likert scales were highly suitable for
use with children [111].
In sum, Likert scales appear to be appropriate for most
pediatric PRO measures, as indicated by qualitative research,
expert opinion, children’s opinions, and a substantial number of
questionnaires that have used the scales in the past. However,
Likert-scale items are not appropriate for all pediatric measures
across age groups. Two studies have reported consistent ﬁndings
regarding developmental differences in children’s ability to use
the full range of Likert scale response options. Younger children
tend to provide more responses at the highest and lowest levels
of the response scale. In one of the studies, 5- to 6-year-old
children provided more extreme responses than did older chil-
dren when rating emotion-based tasks on both three-point and
ﬁve-point scales [44]. The other study found that the percentage
of extreme responses decreased with age: 87.1% at age 5 years,
78.9% at age 6 years, 61.4% at age 7 years, and 50.4% at ages 8 to
11 years [19]. Findings from these two studies suggest that, for
some items, Likert response scales may be appropriate for older,
but not younger children. Therefore, we recommend evaluating
the response options of a PRO measure with children of the target
age group in cognitive interviews. In these interviews, it will be
important to identify the age at which children begin to use and
understand the full range of the response option scale, rather
than relying on the extreme responses. To be considered
adequate for PRO measures used in regulatory submissions,
response options must also meet criteria described in the FDA
PRO guidance [1], including clear distinction between response
choices, clear wording, and adequate instructions (possibly
including an example of a completed item).Recall period
A recent review of instruments assessing children’s HRQOL
reported that many commonly used child-reported measures
have a recall period of the past 4 weeks or the past month [14].
These instruments include the CHIP [79,112], the Child Health
Questionnaire [15], and the PedsQL [113]. Measures, such as these
three, with relatively long recall periods have clearly yielded
important information about children’s health in many clinical
trials and other studies. However, instruments with recall periods
as long as 1 month may be met with skepticism if used as the
basis for a claim in medical product labeling.
The FDA PRO guidance [1] says,
PRO instruments that call for patients to rely on memory,
especially if they must recall over a long period of time … are
likely to undermine content validity. Response is likely to be
inﬂuenced by the patient’s state at the time of recall. For these
reasons, items with short recall periods or items that ask
patients to describe their current or recent state are usually
preferable.
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period because the choice of the recall period depends on a wide
range of factors, including the instrument’s purpose as well as
the duration, frequency, and intensity of the concept being
measured. The guidance adds that the appropriateness of a recall
period should be evaluated with regard to patients’ “ability to
validly recall the information requested.”
There is some indication that children’s ability to accurately
use recall periods varies among child age groups. For example,
one study found that children younger than 8 years were less
likely than older children to be able to report the last time a
symptom occurred in the past 4 weeks, and it was not clear that
5- and 6-year-old children understood the concept of a week or a
month [19]. A study with parent-child dyads also highlighted
children’s limitations in using recall periods [71]. In this study,
children sometimes appeared to lack the cognitive skills neces-
sary for comprehending time frames, and parents often helped
their children remember health-related difﬁculties by linking the
time frame to speciﬁc events and activities. Results were not
presented by age, but 69% of the sample was between 8 and 10
years old, suggesting that some children within this age range
may have difﬁculty with recall periods. Another recent study
examined the effect of “retention interval” (i.e., elapsed time
between the assessment and the event to be reported) on the
accuracy of children’s memory for meals [114]. In this sample of
fourth-grade children (i.e., roughly 9 years old), the accuracy of
memory of school breakfasts and lunches was improved by
shortening the retention interval. This ﬁnding highlights the
importance of using shorter recall periods for child-reported
measures. PRO instrument developers are likely aware that
children could have more difﬁculty with recall periods than do
adults. For example, the Child Asthma Quality of Life Question-
naire has a recall period of 1 week, which was reduced from 2
weeks in the adult version of the instrument [115].
In sum, shorter recall periods are preferable for PRO measures
used in the regulatory context, and this may be more important
for pediatric measures than for adult measures. This task force
believes that recall periods of 24 hours or less are likely to be
viewed more favorably than longer recall periods in the regula-
tory context based on the FDA PRO guidance recommendation for
shorter recall periods and research demonstrating children’s
difﬁculties comprehending longer time frames. Furthermore, a
momentary assessment approach (i.e., assessing the child’s
perceptions of his or her current state) may be useful because it
avoids any problems that could be caused by children’s under-
standing of a period of time.
It is not possible, however, to provide a speciﬁc recall period
that will be optimal for all pediatric studies, and longer recall
periods may be acceptable in some situations if adequate justi-
ﬁcation is provided. Shorter recall periods may also have dis-
advantages, such as the need for more frequent measurement
and the possibility that assessments could fail to capture impor-
tant health-related symptoms or events that occur outside the
speciﬁed recall period. In addition, it may be advantageous for
data collection and interpretation for PRO measures to have recall
periods that are consistent with clinical measures in a particular
trial. Some therapeutic areas such as psychiatry tend to use
clinician-reported measures with recall periods of 1 week, and a
PRO with a shorter recall period would introduce inconsistency
that could interfere with interpretation of ﬁndings. All these
factors will need to be considered when determining the appro-
priate recall period, and cognitive interviews are likely to be
important in justifying a recall period for each purpose, instru-
ment, and age group. To inform future decisions about recall
periods, research is needed on the accuracy of children’s memory
for health-related concepts across various time frames, and these
studies should be conducted within narrow age groupings.Length of instrument
The length of a pediatric PRO questionnaire requires careful
consideration because of the wide variation in children’s ability
to maintain attention to tasks [16]. It is generally believed that
instruments designed for use in younger children face more
length limitations than do those designed for use in older
children and adults. It has also been suggested that younger
children require shorter instructions than do older children [47].
Measures that are overly long may cause children to omit items
or think less carefully about each item, thus yielding less
accurate and reliable data [9]. In consideration of these issues,
one approach has been to create multiple versions of a single
instrument, varying in length and targeted at different age groups
[105]. Pilot testing and cognitive interviews in children of the
target age range will help determine whether the length of the
instrument is appropriate for the target age range, prior to
including the instrument in a clinical trial.Pictorial representations
Instrument developers have often included pictorial representa-
tions of concepts and response options in pediatric PRO measures
[14]. There is little empirical data demonstrating the advantages
of these illustrations, although one study did ﬁnd that a pediatric
questionnaire with illustrations was signiﬁcantly faster to com-
plete than a version without illustrations, suggesting that the
cartoon version may engage the child more effectively [116].
Despite minimal empirical support, many researchers believe
that these pictorial approaches may help younger children
complete questionnaires. It is theorized that pictures can help
maintain children’s interest, sustain attention, increase item
comprehensibility, clarify the response process, and therefore,
foster more meaningful responses [9]. More research is needed to
examine and conﬁrm these potential beneﬁts, but based on the
opinions of experts and the many instruments that have used
this approach, it seems likely that pictures may be helpful for
some younger children.
Several pictorial approaches have been used. The simplest
approach to make response options more concrete may be to use
circles of increasing sizes. For example, the CHIP-CE requires
children to respond to items by choosing one of several response
options [112]. There is a circle above each response, and these
circles increase in size as the response options progress from
“never” to “always” (Fig. 4). Response options may also be
represented by simple drawings of faces, with expressions that
indicate neutrality or various degrees of positive or negative
emotion (Fig. 5) [105,117–119]. This “smiley face” approach has
been recommended for use with young children by 80% of the
participants in a Delphi panel conducted during the development
of the KIDSCREEN quality-of-life measure [111].
There are also examples of questionnaires using more elab-
orate drawings to illustrate items and response options. The
CHIP-CE has illustrations of children representing the extreme
responses of the Likert response scale for each item (Fig. 4) [112].
Other measures have used cartoon-like illustrations intended to
help children understand item content, including drawings of
children representing psychiatric diagnoses (Fig. 6) [120] and
cartoons of dogs representing pediatric dermatological symptoms
[116].
Results of one study, however, suggest that researchers
should be cautious when using these pictorial approaches.
Chambers and Craig [118] compared two types of pain rating
scales using faces as response options in a sample of 100
children. One of the scales included a neutral face as the “no
pain” anchor, whereas the other scale had a smiling face as the
“no pain” anchor (Fig. 7). The two types of scales yielded
signiﬁcantly different item scores, with the direction of difference
Fig. 4 – Example of a response scale using illustrations and
circles of increasing sizes to clarify response options.
This item is presented here as an example of a PRO item
using pictorial representations to help children understand
the response scale. However, other aspects of this item are
not optimal for use in the regulatory context. For example,
the recall period is relatively long, and the response options
require the child to average their experience of the symptom
over this 4-week period. This is a complex averaging task,
and children’s memory is unlikely to be accurate for a 4-week
period. Therefore, regulatory reviewers may have an
unfavorable view of this item. PRO, patient-reported outcome.
Reprinted from Med Care, 42, Riley AW, Forrest CB, Rebok
GW, et al., The Child Report Form of the CHIP-Child Edition:
reliability and validity, 221–31, 2004, with permission from
Lippincott Williams & Wilkins.
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illustrations must be designed and tested as rigorously as other
aspects of the questionnaire because these illustrations could
confound results and undermine validity. Another possible risk
of illustrations is that some adolescents could perceive them as
overly childish. As with other aspects of questionnaire design,
cognitive interviews can be used to examine children’s percep-
tions and understanding of pictorial representations.Other formatting details
Other formatting details that may initially seem less important
could also have an impact on the clarity and validity of a
pediatric PRO measure. Maintaining a clear layout of items with
sufﬁciently large print may enhance readability, particularly for
younger children. These types of formatting issues are rarely
discussed in the published literature, but there is some indicationFig. 5 – Example of a response scale with facial expressions illu
Reprinted from Eur J Oncol Nurs, 14, Tomlinson D, Gibson F, Tre
Mucositis Evaluation Scale (ChIMES): child and parent perspectiv
29–41, 2010, with permission from Elsevier.from previous research that these are not trivial concerns. For
example, the format of the Child Oral Health Impact Proﬁle was
revised with increased font size and shading for every other item
as a result of qualitative interviews [103]. Furthermore, in the
cognitive interviewing study for the PROMIS pediatric item bank,
child respondents suggested making the font larger and stating
the recall period in bold type for additional clarity [47].Administration approaches
When developing and implementing adult PRO measures,
researchers can generally assume that most patients can com-
plete questionnaires independently. However, children differ in
their ability to independently complete questionnaires. There-
fore, when developing pediatric PRO measures, researchers will
need to consider a variety of administration approaches that
differ in the degree of independence expected of a child respond-
ent. Older children and adolescents can often be expected to
complete written questionnaires independently. Younger chil-
dren may require interviewer-administered measures or parental
assistance to overcome limitations in reading ability and atten-
tion. For example, the Childhood Asthma Questionnaire was
developed with three forms, corresponding to three age ranges
[105,119]. The form for the youngest age range (4–7 years old) is
completed by the child with a parent’s help, the form for the
middle age range (8–11 years old) may be completed with adult
help if necessary, and the form for the older age group (12–16
years old) was designed to be completed independently (see
“Conclusions and Recommendations for Future Research” later
in this report for discussion of challenges combining data from
multiple age-speciﬁc versions of an instrument). Other types of
administration approaches, such as electronic data collection
(see below) or the use of props, may also help enhance children’s
attention and comprehension during the measure completion
process [24].
The choice of administration approach will depend on several
factors, including the children’s age and the complexity of the
constructs being assessed. The administration approach should
be considered carefully during the qualitative phase of instru-
ment development. For example, if cognitive interviews suggest
that children are having difﬁculty completing a measure inde-
pendently, perhaps a less independent administration approach
would yield more valid data. As discussed in Good Research
Practice 2, however, the presence of a parent or another adult
could bias or inhibit the child’s responses. Therefore, this task
force recommends that parents and other adults should assist
children with PRO instrument completion only when truly
necessary.
To ensure successful data collection, it is essential that project
staff members who administer interviews and other study meas-
ures are adequately trained. Training is particularly important for
open-ended procedures such as concept elicitation interviews,strating each response option.
ister N, et al., Reﬁnment of the Children's International
es on understandability, content validity and acceptability,
Fig. 6 – Examples of ﬁgures that have been used to illustrate psychiatric disorders in a child-reported questionnaire.
Reprinted from J. Abnorm Child Psychol, 22,Valla JP, Bergeron L, Berube H, et al., A structured pictorial questionnaire to
assess DSM-III-R-based diagnoses in children (6-11 years): development, validity, and reliability, 403-23, 1994. With kind
permission from Springer Science and Business Media.
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 4 6 1 – 4 7 9474which require greater sensitivity and insight from the interviewer.
The process of child and adolescent interviews may differ from that
of adult interviews. Interviewers must have some basic knowledge
of developmental issues as well as strategies for communicating
with children and reading behavioral cues [121]. Recommendations
for interviewing parents and teachers about children’s behavior and
background have also been published [121].
Although this task force report focuses speciﬁcally on PRO
administration, it should be noted that research with children
requires careful attention to all aspects of the data collection
process. For example, researchers will need to develop age-
appropriate language for explaining the study purpose and
procedures to children. Before children begin completing PRO
measures, interviewers or other study staff members should
inform them of the following: what will be required of them,
the purpose of the questions that will be asked, the intended use
of the data, conﬁdentiality procedures, and what to do if they
become uncomfortable or want to stop participating. While some
children will not comprehend the study details as well as do
adults, researchers should make an effort to give children a
general understanding and ensure that they feel comfortable.ig. 7 – Two types of face scales with different anchors for “no p
eprinted from Pain, 78, Chambers CT, Craig KD, An intrusive im
ith permission from the International Association for the StudyElectronic data collection
Electronic approaches to collecting PRO data (i.e., ePRO) may have
signiﬁcant beneﬁts in research with children and adolescents.
Screen-based platforms that may be useful with children include
handheld devices such as smart phones, tablets and touch
screens that operate without the use of a keyboard or mouse,
and desktop or laptop computers [122]. Several published studies
suggest that electronic questionnaire assessment, including
Internet-based administration, with children can be a feasible,
reliable, and valid data collection approach [123–127]. Many
children are familiar and comfortable with screen-based activities,
and one study found that children preferred Internet administra-
tion of a health and behavior questionnaire over a paper version
[123]. If screen-based modes of administration can help children
stay focused and engaged, they may help to improve the quality of
self-reported data while minimizing missing data. Interactive
voice response technology may also be a feasible data collection
approach for some age groups [128]. This convenient approach
involving verbal presentation of questions via telephone may be
easier to process than written questionnaires for some children
with reading or writing limitations.ain.”
pact of anchors in children's faces pain scales, 27–37, 1998,
of Pain.
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tions for development and testing of ePRO measures, including
cognitive interviews, usability testing, and evaluation of equiv-
alence between paper and electronic versions of questionnaires
[52,122]. These previous recommendations for ePRO development
are relevant to measures for children and adolescents. In addi-
tion, the current task force recommends usability assessment of
electronic data collection methods within narrow age groupings
when developing ePRO measures for children. Like self-reported
written questionnaire administration, screen-based technology
relies on the respondent’s reading ability, and ePRO administra-
tion may be effective in one age group, but not in others.
Therefore, researchers will need to document usability across
all applicable age groups for ePRO measures to be considered
useful in the regulatory context.
Good Research Practice 5: Consider Cross-Cultural Issues
When developing pediatric instruments for widespread use, it is
important to consider potential differences associated with
culture and language. Although methods for the translation and
cultural validation of pediatric measures are similar to those used
for adult measures [129–131], pediatric measures may raise
additional issues that need to be considered. For example,
because of differences in educational systems across countries,
the reading ability of children at any given age may vary. Differ-
ences in script among diverse languages may also lead to geo-
graphical variation in literacy within speciﬁc age groups [132].
Therefore, it may be necessary to reassess an instrument’s age-
appropriateness in each new country where it may be adminis-
tered to children. There are also likely to be cultural differences in
the type of information that is conveyed to children about
disease and treatment, as well as differences in the degree to
which children are regarded as independent reporters of their
well-being. In addition, there may be cultural differences in
children’s willingness to talk to interviewers without a parent
present. Such cultural norms will need to be examined as part of
establishing content validity within each new country. Finally,
the impact of disease and treatment on social, emotional, and
role functioning may vary greatly across cultures, depending on
the typical activities of children in the culture.
Therefore, the appropriateness of a pediatric PRO instrument
will need to be reexamined with content validity assessment
within each new culture. This assessment should focus on all
relevant aspects of the instrument including the instructions,
items, concepts, vocabulary, and pictorial representations. In
sum, cross-cultural PRO instrument development for children is
likely to require greater sensitivity and effort than simply follow-
ing the cross-cultural guidelines set forth for adult instruments.
Future research and guidelines may help to clarify speciﬁc steps
that must be taken to translate and validate pediatric PRO
instruments across cultures.Conclusions and Recommendations for Future
Research
The recommendations provided in this task force report should
not be interpreted as concrete rules that must be followed in every
study. Instead, the intention of this task force was to present
general guidance and discuss the important issues that must be
considered when designing, validating, or implementing pediatric
PRO instruments for use in the context of regulatory submissions
and medical product labeling. Each individual study is likely to be
unique, and the optimal measurement approach will depend on
a range of factors, including the child’s age, the medical condition
of the target population, and the constructs being assessed.Furthermore, different PRO approaches and study designs may
be advisable for research that is not intended to support medical
product labeling or regulatory decisions. Therefore, the good
research practices recommended in the current report should be
viewed as a starting point, and each researcher will have to
consider the purpose and context of each individual study.
PRO research with children and adolescents is a relatively
young area of research, and more work is needed to provide
updated PRO instruments and methodological guidance for
future studies. For example, research on optimizing PRO design
for younger children is needed, particularly for children younger
than 8 years for whom self-reported measures often have incon-
sistent reliability and validity. There may be speciﬁc ways to
phrase, present, or format items that will maximize comprehen-
sibility for young children, thus enhancing instrument reliability
and validity. Studies comparing multiple measurement
approaches may help provide more speciﬁc recommendations
than are currently available. In addition, more work is needed to
identify the qualitative research strategies that are most likely to
be effective with younger children. The current report provides
initial recommendations for qualitative methods, but there are
not many published studies that have examined the content
validity of PRO instruments for children. Therefore, additional
research is needed to examine and reﬁne these methods. As
more qualitative research with this population is conducted and
published, the methodology is likely to evolve.
When informant-reported outcome instruments must be
used, there is a growing emphasis on developing truly observa-
tional items, rather than proxy measures that require inference
into the child’s subjective experience. Therefore, it may be useful
to update and validate commonly used parent-reported and
clinician-reported instruments to reﬂect this more observational
approach.
Another challenge involves the interpretation of data from
multiple age groups. Many PRO measures for children are
developed with multiple versions for different age groups. Item
content, response scales, vocabulary, pictorial representations of
response options, and other instrument characteristics may vary
across the age-speciﬁc versions to ensure that each version is
appropriate for a speciﬁc age range. The reporter may also vary,
with parents reporting for younger children while older children
complete questionnaires themselves. This “multiple versions”
approach can ensure that a particular instrument examines age-
appropriate content with age-appropriate assessment procedures
throughout a broad age range. When PRO research is conducted
in the regulatory context, however, the goal is often to support a
single labeling claim, rather than individual claims for each
narrow age group. Therefore, the use of multiple versions raises
the question of how data from different versions or even different
reporters can support a single claim across childhood. One
possible analytic approach is to pool data from multiple versions
in a single analysis, but it would be necessary to demonstrate
that content and measurement properties of all versions are truly
equivalent and comparable. Another approach is to analyze
different versions separately and examine whether treatment
outcome trends are similar across age ranges and versions of the
instrument. Future research is needed to provide guidance on
strategies for analyzing and interpreting data gathered with
multiple age-speciﬁc versions of a single PRO instrument.
It can also be challenging to interpret data from parents and
children completing parallel forms of the same instrument. In
some situations, both parents and children may be able to
provide useful information, but it is not clear how results should
be interpreted if the two reporters have different perceptions of
the same construct. Furthermore, with increasing emphasis on
limiting informant-reported measures to observable domains (as
discussed in Good Research Practice 3), some parent-reported
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forms, which may include more subjective content. Therefore,
when gathering data from both parents and children, it may be
best to specify a priori that data from one of these reporters will
be considered the primary end point. More research is needed to
provide guidance for taking both children’s and parents’ perspec-
tives into account, even when they diverge.
Additional research is also needed to examine the responsive-
ness of pediatric PRO instruments. Responsiveness is the extent
to which a health status measure accurately detects change in a
patient’s condition over time [133–135]. In the regulatory context,
responsiveness is necessary for a PRO measure to be considered
ﬁt for the purpose of “identifying differences in scores over time
in both individuals and groups who have changes with respect to
the measured concept” [1]. As reported in the discussion of Good
Research Practice 1 in the current report, reliability and validity
have been analyzed and reported for many PRO measures
designed for children and adolescents. Relatively little data on
responsiveness of pediatric PRO measures, however, have been
published [14]. Given the importance of accurately detecting
change in studies conducted to support medical product labeling,
this task force recommends evaluating the responsiveness of any
pediatric PRO measure used in this context.
Although this task force report focuses primarily on the
development of new PRO instruments, the recommendations
and discussion can also apply to the use, evaluation, and
modiﬁcation of existing PRO measures designed for use in
children. Issues pertaining speciﬁcally to the use and modiﬁca-
tion of existing instruments have been discussed in detail by a
previous ISPOR task force [54].
One limitation of this task force was the narrow focus on
pediatric PRO assessment in the context of research conducted for
regulatory submissions. Health outcomes research outside this
regulatory context was considered to be outside the scope of this
report, but it should be noted that other areas of research on
children and adolescents also raise important methodological
challenges. For example, health state utility valuation is necessary
for deriving quality-adjusted life years (QALYs) in cost-utility
modeling submitted to reimbursement authorities and other
decision makers. However, valuing childhood health states raises
unique challenges [136–138]. Childrenmay not be able to conceptu-
alize the abstract concepts necessary for direct utility assessment
such as time trade-off and standard gamble tasks, and common
utility assessment methods used for adults often do not apply to
pediatric health states. Furthermore, given the rapid physical and
cognitive development of childhood, child health states are less
likely to remain stable than adult health states, and evaluation of
temporary health states is complex [139]. Still, cost-utility analyses
are frequently conducted to model treatment of childhood health
conditions, and utilities for pediatric health states are necessary to
quantify children’s quality of life for these models [140]. Conse-
quently, researchers have been working to develop health utility
measures speciﬁcally for children and adolescents [141–144].
Another growing area of research with the potential to inﬂuence
clinical and policy decision making is comparative effectiveness
research (CER). It has been suggested that methods and concepts of
CER may differ when examining treatments for children rather
than adults [145]. Because of the speciﬁc focus on PROs in the
regulatory context, the current task force did not address these
areas of research, but it is hoped that future research will continue
to examine child-speciﬁc issues in a broad range of contexts such
as health state utility valuation and CER.
Several other important topics related to pediatric research were
not covered in the current report. For example, evaluation of drugs
in children raises unique ethical issues, which are discussed in
detail in the published guidelines from the American Academy of
Pediatrics [146]. Issues related to the recruitment of childrenfor randomized clinical trials have also been discussed previously
[147].
With additional PRO studies in children and adolescents,
conﬁdence in pediatric PRO instruments and methodology will
continue to grow. Furthermore, as PRO data are increasingly used
to support labeling claims, there will be more information
regarding the standards by which these instruments will be
judged. As this area of research continues to develop, the use of
PRO instruments in clinical trials and regulatory submissions will
help ensure that children’s experience of disease and treatment
is accurately represented and considered in regulatory decisions.Acknowledgments
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